Completed PHASE2 INTERVENTIONAL 3-arm NCT01425788

Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense (Osiris)

Sponsor: ACM Pivotal Global Central Laboratory

Updated 5 times since 2017 Last updated: Jun 25, 2015 Started: Aug 31, 2011 Primary completion: Nov 30, 2011 Completion: Feb 29, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01425788, this PHASE2 trial focuses on Rhino-conjunctivitis and remains completed. Sponsored by ACM Pivotal Global Central Laboratory, it has been updated 5 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ACM Pivotal Global Central Laboratory
ALK-Abelló A/S
Brecon Pharmaceuticals Ltd
Ergomed

Data source: ALK-Abelló A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lodz, Poland